No products in the cart.
Pre-made Prasinezumab benchmark antibody ( Whole mAb, anti-SNCA therapeutic antibody, Anti-NACP/PARK1/PARK4/PD1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-455
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Prasinezumab biosimilar, Whole mAb, Anti-SNCA Antibody: Anti-NACP/PARK1/PARK4/PD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Prasinezumab is a humanized IgG1 monoclonal antibody directed against aggregated ¦Á-synuclein. Genetic and pathological evidence suggest that this protein plays a central role in the pathogenesis of Parkinson’s disease (PD) and other ¦Á-synucleinopathies such as dementia with Lewy bodies (DLB).
| Products Name (INN Index) | Pre-Made Prasinezumab biosimilar, Whole mAb, Anti-SNCA Antibody: Anti-NACP/PARK1/PARK4/PD1 therapeutic antibody |
|---|---|
| INN Name | Prasinezumab |
| Target | SNCA |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | Neotope Biosciences,Chugai Pharmaceutical,Prothena,Roche |
| Conditions Approved | NA |
| Conditions Active | Parkinson's disease |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | SNCA |
| Package |
Previous slide
Next slide
